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Abstract
Shackelford, Hannah Blythe. MS. The University of Memphis. May 2012.
Characterization of Bone and Brain abnormalities associated with Berkeley Sickle Cell
Mice. Major Professor: T. Kent Gartner
Sickle Cell disease (SCD) is one of the most severe, monogenic, autosomal
recessive disorders in the world. SCD causes devastating pain, inflammation, organ
damage, vaso-occlusion and bone damage. The Berkeley mouse model is useful for the
evaluation of the disease because the animals present symptoms similar to the human
condition. The data presented in this study demonstrate that SCD causes bone
abnormalities in the Berkeley mouse model similar to those present in humans.
Specifically, SCD causes significant decreases in bone mineral density and bone mineral
content of the BERK mice in the whole body, cervical and lumbar vertebrae and femur.
Also, Peripheral inflammation associated with SCD increases the permeability of the
blood brain barrier and enables infiltration of monocytes into the brain. Although the
BERK model has been characterized extensively, SCD effects on bone structure and the
ability of immune cells to permeate the brain have not been described.
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INTRODUCTION
Sickle Cell Disease is one of the most common severe genetic disorders found
throughout the world. It can be described as a multisystem disease, in which episodes of
acute illness occur that eventually lead to chronic organ damage. Linus Pauling
designated sickle cell disease the first “molecular disease” in 1949, after observing the
abnormal hemoglobin using electrophoresis. The term sickle-cell disease encompasses
many different genotypes, which all result in the clinical disorder. The most common
form of sickle cell disease is sickle cell anemia; it results from a mutation in the β-globin
gene producing sickle hemoglobin, Hbs, in individuals homozygous for the mutation
(Rees, Williams, & Gladwin, 2010). Specifically, the mutation occurs in the 17th
nucleotide of the β-globin structural gene. The transition mutation substitutes an adenine
for a thymine, so that the sixth amino acid in the polypeptide chain is changed from
glutamic acid to valine (Bunn, 1997). This amino acid change initiates binding of two βglobin chains, β 1 and β 2, of two different hemoglobin molecules that result in
polymerization of the hemoglobin molecules within red blood cells. The polymerized β globins accumulate within the erythrocyte, which disturbs its flexibility and leads to
cellular dehydration and oxidative stress and eventually produces a sickled erythrocyte
(Brittenham, Schechter, & Noguchi, 1985). The formation of distorted red blood cells
leads to obstruction of blood flow, which can cause tissue ischemia and necrosis, further
enhancing the rate of hemolysis (Buchanan et al., 2010)
Hemolysis results in the release of free hemoglobin and iron into circulation, and can
lead to endothelial dysfunction, vascular disease and thrombosis (Woollard, Sturgeon,
Chin-Dusting, Salem, & Jackson, 2009). Nitric oxide is an important cellular messenger
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produced by the endothelium, with inhibitory roles in endothelium and platelet activation
as well as expression of cellular adhesion molecules (De Caterina et al., 1995; Palmer,
Ashton, & Moncada, 1988). Once hemolysis occurs, hemoglobin is released into the
plasma where it inhibits nitric oxide signaling by scavenging nitric oxide molecules in
circulation. The scavenging of nitric oxide by cell-free hemoglobin leads to
dioxygenation and nitrosylation of nitric oxide (Palmer et al., 1988) and results in
endothelial dysfunction and nitric oxide resistance. The polymerization of hemoglobin S
leads to the disruption of the erythrocyte membrane and destruction of approximately
10% of the total number of erythrocytes each day, where the free hemoglobin that is
released is sufficient for scavenging nitric oxide (Reiter, 2002).
The severity of the disease depends on many factors including the age of the patient,
the specific genotype inherited and environmental factors such as stress. Also, tissue
damage varies depending on the genotype, and can affect the lungs, heart, kidneys and
bones and to other organs. Some common complications resulting from the hemolysis
and anemia are pulmonary hypertension, osteonecrosis, chronic renal disease and
cognitive dysfunction.
At this time, the only cure for sickle cell disease is bone marrow transplantation
(BMT), and the few available treatments are not very effective. Although bone marrow
transplantation of hematopoetic stem cells is currently the only method to cure SCD, it is
difficult to find donor matches, and developmental problems have been reported for
young patients after undergoing bone marrow transplantation (Buchanan et al., 2010).
Also, BMT would be more beneficial when performed on young patients to preclude the
accumulation of extensive organ damage for a better quality of life. Treatments for pain

2	
  

and organ damage are hydroxyurea, hydroxycarbamide and blood transfusions. All three
current treatments have some adverse effects and some patients are too sick to endure
treatment.
In addition to days of work lost, the economic costs of SCD are extensive. A research
study performed by the Florida Medicaid program from January 2001 to December 2005
assessed the annual cost of SCD. Sickle cell patients from age 0-9 accrued an average
annual cost of $10,704 and this rose to an average of $34,266 for patients from ages 3039 years (Kauf, Coates, Huazhi, Mody-Patel, & Hartzema, 2009). So, more thorough
evaluation of the pathophysiologies associated with SCD needs to occur in order to
develop more cost-efficient and effective treatments for patients suffering from the
disease.
Two major pathophysiologies associated with SCD are vaso-occlusion and hemolytic
anemia. The pain thought to result from vaso-occlusion may be caused by the ischemia,
which results from vascular obstruction by the sickled erythrocytes. The rigidity of the
red cell membrane characteristic of sickled RBCs prevents them from passing through the
vascular lumens of small vessels. In addition to HbS polymerization, entrapment of the
red blood cells in microcirculation is mediated by the inflammatory response (Rees et al.,
2010). Previous studies using transgenic sickle mice have shown that treatment with
inflammatory drugs enhances erythrocyte adhesion within the vasculature (Frenette,
2002; Osarogiagbon et al., 2000). Vascular occlusion results from the interaction between
the endothelium and the circulating erythrocytes adherent to leucocytes (Rees et al.,
2010). This interaction between the endothelium and red blood cells promotes occlusion
when the erythrocytes prevent sufficient blood flow, which in turn leads to ischemia.
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Reperfusion can occur once the erythrocytes are pushed through the blood vessel, but this
can be problematic and results in further vascular damage (Rees et al., 2010). The
ischemia-reperfusion cycle produces oxidative stress, which can further activate the
inflammatory response by eliciting synthesis of inflammatory cytokines (Belcher et al.,
2003; Frenette, 2002).
Hemolytic anemia is another pathophysiological process characteristic of SCD. In
addition to vaso-occlusion, hemolytic anemia is a consequence of HbS polymerization
and can result in vascular pathologies such as pulmonary hypertension (Rees et al., 2010).
Hemolysis releases free hemoglobin into circulation, and free plasma hemoglobin
generates reactive oxygen species that scavenge nitric oxide (Reiter, 2002). Reactive
oxygen species (ROS) are chemically reactive molecules that form as a natural byproduct
of oxygen metabolism. ROS can have important roles in cell signaling. During enhanced
stress, increases in ROS can damage cell structures and trigger oxidative stress. HbS has
been implicated in enhanced auto-oxidation, as well as increased levels of superoxide and
hydroxyl radicals within red blood cells of SCD patients (Hebbel, Eaton, Balasingam, &
Steinberg, 1982).
Characterization of bone abnormalities associated with SCD, including detailed
quantitative studies, has not been previously described. Previous studies have shown a
correlation with iron deposition and bone necrosis, but lack a more in depth analysis of
the detrimental effects on bone. Patients with SCD undergo regular blood transfusions
that can contain a higher concentration of iron bound to hemoglobin than is required to
maintain normal iron homeostasis. This can be harmful because excess iron is not
excreted; rather it accumulates in bones and tissues. Specifically, osteoporosis and bone
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fractures can result from iron accumulation (Tsay et al., 2010) In addition, cortical and
trabecular abnormalities have been described as a consequence of iron accumulation,
with involvement from enhanced ROS and pro-osteoclastogenic cytokines. Tumor
necrosis factor (TNF-α) and interleukin-6 are examples of cytokines reported to promote
bone degradation (Tsay et al., 2010). Bone Mineral Density (BMD) and Bone Mineral
Content (BMC) are measurements that determine the quality of bone. BMD
measurements can be taken from 2-dimensional and 3-dimensional sources. Dual energy
X-ray apparatus (DEXA) is a two-dimensional method of screening the amount of bone
in the subject and measures both BMD and BMC. Micro-computed tomography (microCT) gives a three-dimensional analysis of the morphology of the bone, and gives a more
in depth analysis than DEXA. Information from both DEXA and micro-CT provide
characterization of bone quantity and quality. These analyses are important markers of
the overall health of the bone, as well as indicators of diseases that affect bone such as
osteoporosis.
In patients suffering from SCD, inflammation results from recurrent ischemia and
reperfusion, which attracts monocytes and macrophages to the areas of injury. Monocytes
are antigen-presenting leukocytes present in circulation that play critical roles in
inflammation, T-cell differentiation, phagocytosis and acquired immunity (Bao, Kim,
Bhosle, Mehta, & Cho, 2010). Enhanced monocyte production and recruitment into the
brain often results in stroke or cerebral inflammatory disease (Bao et al., 2010; D'Mello,
Le, & Swain, 2009). D’Mello et al showed an eight-fold increase in monocyte
recruitment into the brain of mice with hepatic inflammation. Specifically, monocyte
infiltration was reported in the hippocampus and striatum regions of the brain (D’Mello
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et al., 2009). Since SCD increases the permeability of the blood brain barrier and is
associated with an enhanced inflammatory response (Manci et al., 2006), the
investigation of monocyte infiltration into brain regions such as the striatum and
hippocampus could provide insight into the extent of infiltration and further
characterization of the disease.
Sickle cell disease is a genetic disorder characterized by broad-spectrum
inflammation, a component of the feedback loop involving vaso-occlusion and hemolytic
anemia. Although many pathophysiologies have been attributed to the disease, there are
not many effective treatments to alleviate the pain or tissue damage resulting from the
continuous inflammatory environment. Therefore, more experimentation is required to
understand the consequences of inflammation, and characterize the abnormalities
associated with the disease. Furthermore, understanding of consequences of SCD-elicited
inflammation on the development of bone abnormalities and monocyte infiltration of the
brain may justify using the BERK mouse model for testing potentially clinically useful
therapeutic agents. The results of these studies may provide a rationale for the use of
therapeutic treatments to alleviate and/or prevent the pathophysiological changes and
complications that result from inflammation. Evaluation of BERK mice as a model for
testing therapeutic agents to treat and/or prevent the development of bone abnormalities
and monocyte infiltration of the brain are the primary objectives of this study.
Statement of Research Objectives
The overall goal of this thesis is to characterize the bone and brain abnormalities of
Berkeley Sickle Cell Disease (SCD) mice to provide SCD-related information not or
superficially described in the literature. After characterization of bone deficiencies that
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occur as a consequence of SCD, treatment with a potentially therapeutic agent could
prevent or diminish the extent of the development of SCD-related skeletal and brain
abnormalities. Since there is a lack of therapeutic treatments for sickle cell disease, there
is a pressing need to characterize the effects of the disease on the bones and brain.
The first research objective is characterization of mouse skeleton for abnormalities
associated with Sickle Cell Disease. The skeleton was characterized using three different
techniques. A low voltage, low resolution PIXImus2 machine was employed to measure
bone composition using dual-energy x-ray absorptiometry (DEXA). This method is
useful for determining the bone mineral density (BMD) and bone mineral content (BMC)
of the sickle cell disease mice for comparison with healthy mice. In addition, highresolution micro tomography (Micro-CT) was be used to compare the cortical and
trabecular bone regions of SCD mice to C57/Bl6 mice. The third technique measured the
amount of flexure stress required to break the femur.
The second objective is to assess the effects of the anti-reactive oxygen species agent
N-acetyl-L-cysteine (NAC) on progression of bone abnormalities in Sickle Cell mice.
Reactive oxygen species are produced in response to hemolysis, which induces the
inflammatory response, and the resulting enhanced inflammation may be responsible, at
least in part for the development of severe bone abnormalities and damaged brain tissue.
NAC has been proven as a therapeutic agent in reducing reactive oxygen species, and
will be investigated as a possible treatment for the symptoms of sickle cell disease.
The third objective is to assess monocyte infiltration in the brain due to increased
permeability of the blood brain barrier. The blood brain barrier in Berkeley SCD mice is
more permeable than in normal mice. The increased permeability of the blood barrier
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may be due to the increased inflammation associated with sickle cell disease. Normally,
monocytes do not pass from the periphery into the CNS, but in instances of systemic
inflammation they have been reported in the several brain regions. Since inflammation
apparently elicits many of the symptoms characteristic of SCD, it is likely that monocytes
penetrate into brain tissue of SCD mice, and patients.
Materials and Methods
i. Animals
The Berkeley Sickle Cell mice used for bone characterization were received from
St. Jude Children’s Research Hospital. The Berkeley mice are transgenic and express
exclusively human sickle cell hemoglobin, designated hemoglobin S (HbS). Mouse αand β-globin genes were eliminated and replaced with the human globin genes because
those molecules inhibit sickling of human HbS. This was accomplished, in part, by using
human γ-, β-, and α-genes together as a transgene to introduce the human hemoglobin
gene into the mice. The transgene results in expression of human α- and βs-globin instead
of mouse α-and β –globin (Paszty et al., 1997).
The Sickle Cell mice used for the N-acetyl-L-cysteine trial were produced by
bone marrow transplantation at the University of North Carolina. Bone marrow was
harvested from two hemizygous SCD mice, and transplanted into twenty-four lethally
irradiated, 8 week old female C57Bl/6 mice. In this manner, 23 BERK bone marrow
transplant (BMT) mice were produced that exclusively expressed human HbS, after
repopulation of the depleted bone marrow by donor cells. Specifically, the lethally
irradiated marrow recipient mice received the BMT at 8 weeks, and were allowed to
repopulate the bone marrow to 11 weeks post-BMT, before undergoing experimentation.

8	
  

The mice were separated into three groups; time zero, control and experimental. Three
animals were euthanized at 19 weeks to serve as control animals at time zero (before
experimentation). Whole body scans, excluding the skulls, were performed using a GE
Lunar PIXImus2 peripheral dual-energy x-ray apparatus (DEXA). Next, the right hind
femur and lumbar vertebrae were paired for micro-computed tomography, and the left
hind femur from each mouse was used for mechanical testing. The femurs and vertebrae
for micro-CT were stored in 70% ethanol and the femurs for mechanical testing were
wrapped in 0.9% saline-soaked gauze and frozen at -40 °C.
Ten mice were given the antioxidant N-acetyl-L-cysteine (NAC) (Sigma-Aldrich:
100 mg/kg once a day) by subcutaneous injection five times a week for 12-24 weeks.
Phosphate-buffered saline (1X) was used as the vehicle to solubilize the NAC (pH
adjusted to 7.4 then filter sterilized). Ten mice were placed in the NAC experimental
group, animals 1-5 were injected (30G ½ inch, 100uL subcutaneously) for 12 weeks and
animals 6-10 were injected for 24 weeks. Then, ten mice were separated into two control
groups, 5 uninjected and 5 vehicle-injected. The vehicle-injected (5 times a week,
subcutaneously) mice were injected with PBS (1X) buffered to physiological pH of 7.4.
After euthanizing the time zero mice, 10 animals began subcutaneous NAC-injection, 5
animals began subcutaneous vehicle injection (C) and 5 animals received no treatment
(U).
ii. Bone Analysis
Whole animal bone scans, excluding the skulls, were performed using the PIXImus
to measure bone mineral density (BMD) in g/cm2 and bone mineral content (BMC) in
grams. Regions of interest (ROI) were selected based on significant differences between
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the homozygous and hemizygous sickle mice. In order to assess the progression of the
disease and the effects of the NAC treatment, 10 animals were euthanized and scanned at
12 weeks and the other 10 mice were euthanized and scanned at 24 weeks. The DEXA
data were collected and expressed graphically as mean ± SEM.
High-resolution micro-computed tomography (Micro-CT µCT 40 Scanco Medical,
Basserdorf, Switzerland) was used to produce high-resolution, three-dimensional cross
sections of the femurs and lumbar vertebrae. Cortical and trabecular bone of the middiaphyses of the femurs, as well as the lumbar vertebral bodies were analyzed to produce
values for cortical thickness (µm), BMD (g/cm3), cortical volume (mm3), and marrow
volume (mm3). For trabecular bone analysis, values were obtained for trabecular
separation (mm) and trabecular number.
Mechanical data was calculated by testing the strength of the bones using an Instron
Universal System (Instron Corp., Norwood MA, model 5567) and reported in Newton’s.
iii. Immunohistochemical analysis
Mice were euthanized by CO2 inhalation, and then their brains were removed and
immersed overnight in 4% buffered paraformaldehyde at 4° C. After fixation, the brains
were placed in 25% sucrose in dH20 and stored at 4ºC for sectioning. For cryosectioning,
tissue was frozen on dry ice and sections were cut at 20 or 30µm using a sliding
microtome (Leica CE, Model SM2000R). Sections were stored in cryoprotectant until
processed using the avidin;biotinylated enzyme complex method (ABC; Elite Vectastain
ABC kit, Model PK-6100) for detecting monocytes. To remove the cryoprotectant, the
free-floating sections were rinsed with potassium phosphate buffered saline (KPBS) six
times over the course of one hour. Then, the sections were incubated in 0.014%
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phenylhydrazine at room temperature. The tissue was rinsed for one hour with KPBS
before non-specific binding was blocked with normal goat serum (Vector Laboratories,
S-1000) diluted to 10% in KPBS. The sections were incubated with a monoclonal
antibody against monocytes (Moma-2, rat anti mouse macrophages/monocytes; AbD
Serotec) diluted in Tris buffered KPBS (pH 7.4) to a concentration of 1:250 for one hour
at room temperature then 40-72 hours at 4°C. The sections were washed for one hour
with KPBS then incubated with a biotin-labeled secondary antibody (biotinylated anti-rat
IgG; Vector) followed by five washes with KPBS. Then the sections were incubated with
the A/B solution, rinsed with KPBS and rinsed with 0.175M sodium acetate before
incubation with a diaminobenzidine (DAB) peroxidase substrate kit (3,3’diaminobenzidine; Vector laboratories) for monocyte visualization. Finally, sections were
mounted on Superfrost Microscope slides (Fisherbrand) and coverslipped with
Histomount (National Diagnostics) for observation under the microscope (Kramer,
Simmons, & Freeman, 2008)
iv. Statistical analysis
Results are presented as mean plus or minus standard error of the mean (SEM). Each
group contains 5 animals except the time zero group, which contains 3 animals.
Differences between the groups were evaluated by a Student t test, and p values were
statistically significant at p < 0.05.
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CHAPTER 1: BONE CHARACTERIZATION
Sickle Cell disease results in abnormalities of the bone, for example osteopenia is
common. A quantitative evaluation of the development of bone abnormalities as a
consequence of SCD has not been described for the BERK mouse model. To address this
issue, the skeletons of five female SCD heterozygous mice (SCD +/-) and five agematched male SCD homozygous mice (SCD +/+) were compared by DEXA analysis.
BMD and BMC measurements were taken from a particular region of interest (ROI) from
the five SCD +/+ experimental mice and the five SCD +/- mice, and the averages are
expressed graphically in Figures 1 and 2 and numerically in Tables 1 and 2. The whole
skeleton of each mouse (excluding the skull) was scanned, and a femur/tibia complex was
removed from each mouse and scanned separately. The femur and tibia were selected as
ROIs based on previously described BMD deficiency of the femur as a result of iron
deposition, and because SCD patients require hip replacements with a higher frequency
than the population at large (Tsay et al., 2010).
As a prelude to this investigation, DEXA analysis was used to establish whether or
not there is a gender-based difference in BMD values in C57BL/6 mice. Three male and
three female age-matched C57BL/6 mice were subjected to whole body DEXA analysis
for this purpose. BMD values were measured and the averages are expressed graphically
in Figure 1 and numerically in Table 1. The BMD value is expressed in grams/cm2.
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RESULTS

Bone Mineral Density
0.06
0.05

**

C57Bl/6 M
C57Bl/6 F

**

SCD +/-

0.04
0.03

**

SCD +/+

**

**

0.02
0.01
0.00

Figure 1. Bone Mineral Density (BMD) data for the whole body (WB), cervical (C) and
lumbar (L) vertebrae, and femur + tibia (F+T) complexes. X-ray densitometry was
performed for five Sickle cell disease homozygous mice (SCD +/+) and five Sickle cell
disease heterozygous mice (SCD +/-), and graphs are expressed as means with standard
error. Student t tests indicated that for all ROI’s SCD +/+ mice had significantly less
BMD than SCD +/- mice, as indicated by ** (p < 0.001).
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Table 1. PIXImus2 (DEXA) BMD means ± standard error of the mean (SEM)
for the scans of 10 whole bodies (without skulls), cervical regions of 10 spines,
lumber regions of 10 spines and 10 femur and tibia complexes. Each set
contained 5 SCD+/+, and 5 SCD+/- components. The same region of interest
(ROI) was used for all members of a set of measurements. Two tailed
independent T-Tests were used to compare the means.
Bone Mineral Density
Mean ± SEM
P Value
Whole Body
0.001
SCD+/0.04746 ± 0.001
SCD+/+
0.03866 ± 0.001
Cervical
0.001
SCD+/0.03014 ± 0.00004
SCD+/+
0.02582 ± 0.00007
Lumbar
0.001
SCD+/0.02990 ± 0.0002
SCD+/+
0.02498 ± 0.00004
Femur +Tibia
0.001
SCD +/0.05004 ± 0.0007
SCD +/+
0.0418 ± 0.001

A two-tailed t test was performed to assess whether the differences of the BMD
means between the heterozygous SCD +/- control group and the homozygous SCD +/+
Sickle Cell mice were statistically significant. The p values for the data presented in
Figure 1/Table 1 for the femur/tibia was 0.001, the cervical and lumbar vertebrae was
0.001, 0.006 for the whole body. Average BMD values for the C57BL/6 mice, designated
wild type (WT), were taken and plotted and show higher values for male WT mice when
compared to the BMD values for age-matched female WT mice. This gender-based
difference suggests an even greater significance in the BMD results, since the male SCD
homozygous mice had significantly lower BMD values than female heterozygous mice.
In addition, the vertebrae were selected as a region of interest (ROI) because the effects
on the femur were so dramatic and vertebrae BMD is often reduced in diseases such as
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osteoporosis. Both the cervical and lumbar regions of the spine were measured, and both
regions showed a significantly lower BMD in homozygous mice when compared to the
heterozygous mice.
BMC data were measured in grams from the PIXImus densitometer scans for the
whole body and the femur/tibia; the averages of the data are depicted in Figure 2 and the
averages are presented in Table 2. Two-tailed t test results indicated significantly less
BMC in the SCD +/+ compared to the SCD +/- control group shown in Table 2. The p
value for the femur/tibia was 0.003, for the cervical and lumbar vertebrae was 0.001, and
for the whole body was 0.04. The bone mineral content reflects the total bone mass, and
therefore a reduction in the BMC for the SCD +/+ compared to the SCD +/- supports the
idea that sickle cell disease results in increased bone resorption, and/or abnormal
development of the bone for all ROIs tested.
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Bone Mineral Content
0.24

*

SCD +/SCD +/+

0.18
0.10
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0.08
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Figure 2. Bone Mineral Content (BMC) data for the whole body (WB), cervical (C) and
lumbar (L) vertebrae, and the femur and tibia (F+T) complexes. X-ray densitometry was
performed for five Sickle cell disease homozygous mice (SCD +/+) and five Sickle cell
disease heterozygous mice (SCD +/-), and data are expressed as means with standard
error. Student t tests were performed for each region of interest (ROI) where all values
were statistically significant, as indicated by * (p < 0.05) or ** (p < 0.001).
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Table 2. PIXImus2 (DEXA) BMC means ± standard error of the mean (SEM)
for the scans of 10 whole bodies (without skulls), cervical regions of 10 spines,
lumber regions of 10 spines and 10 femur and tibia complexes. Each set
contained 5 SCD+/+, and 5 SCD+/- components. The same region of interest
(ROI) was used for all members of a set of measurements. Two tailed
independent t-tests were used to compare the means.
Bone Mineral Content
Mean ± SEM
P value
Whole Body
0.04
SCD +/0.2314 ± 0.01
SCD+/+
0.1940 ± 0.001
Cervical
0.001
SCD +/0.041 ± 0.0003
SCD+/+
0.0216 ± 0.002
Lumbar
0.001
SCD +/0.1058 ± 0.001
SCD+/+
0.0502 ± 0.0002
Femur +Tibia
0.003
SCD +/0.0404 ± 0.001
SCD+/+
0.0326 ± 0.002

Since there were significant differences in DEXA BMD and BMC values between
the control and SCD bones, micro-CT was performed on the lumbar vertebrae to further
characterize the bone abnormalities associated with Sickle Cell disease. Figure 3A shows
reconstructions of cross-sectional images from the whole lumbar vertebrae of one SCD
+/+ and SCD +/- mouse, but are representative of all mice in each group. The bone
appears thinner in the reconstruction of the SCD +/+ lumbar vertebrae than the SCD +/vertebrae. Figure 3B shows a reconstruction of the trabecular region of the lumbar
vertebrae where the SCD +/+ had signicantly fewer and thinner trabeculae.
In addition to the lumbar vertebrae, micro-CT was performed on femurs from
both groups of SCD mice. Figure 3C shows two representative cortical reconstructions of
SCD +/- and SCD +/+ mouse femurs. The scale shown with each section reveals that a
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red color represents a higher concentration of mineral content within the bone, whereas
yellow and green color suggests less concentrated mineral content. Figure 3C indicates
SCD +/- mouse femur has a significantly higher mineral density essential for bone
strength than the SCD +/+ (Table 4). In addition to the differences in density within the
cortical region, the SCD +/+ cortical bone region is significantly thinner than the SCD +/(Table 4), which suggests the bone is undergoing improper remodeling and/or abnormal
development as a result of the Sickle Cell disease.

Figure 3. Micro-CT analysis. (A) Reconstructed cross-sectional images from whole
lumbar vertebrae. (B) Reconstructed images of the trabecular bone region of the lumbar
vertebrae (100 slices taken from the anterior end of the vertebral body). (C)
Reconstructed cross-sectional images from the mid-diaphyseal region of the femurs. (D)
Reconstructed trabecular bone from the heads of femurs. Image Processing Language
software from Scanco was used for image reconstruction.

18	
  

Figure 3D shows the observable differences between the trabecular bone of the
femurs of the SCD +/- and SCD +/+ mice. The trabecular bone of the heterozygous
mouse is significantly denser (Table 5) with significantly higher connectivity than the
homozygous mouse bone. There is a significant decrease in the number of trabeculae and
significant increase in the separation between trabeculae of SCD +/+ mouse bones when
compared to the SCD +/- mouse bones (Table 5). These images are from one mouse in
each group, but are representative of all five mice in each group. When the bones were
being removed and cleaned one of the SCD +/+ femurs snapped in half, which
contributes to the idea that Sickle Cell disease results in weaker bones.
The numerical data collected from micro-CT analysis of SCD +/+ and SCD +/femurs are presented in Tables 3-5. The vertebral data presented in Table 3 represent the
reconstructions presented in Figures 3A and 3B. The vertebrae taken from the SCD +/mice significantly decreased connectivity density, trabecular number, apparent BMD,
bone volume and an increase in trabecular separation compared to the SCD +/- vertebrae.
A two-tailed t test was performed for each measurement with statistically significant p
values included in the table.
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Table 3. High-resolution micro-computed tomography from 10 lumbar
vertebrae, 5 SCD+/+, and 5 SCD+/-. The data were collected from a
reconstruction of 100 slices from the anterior end of the vertebral body and
means ± standard error of the mean (SEM) is presented. Two tailed
independent T-Tests were used to compare the means.
Vertebrae Trabecular Data
Mean ± SEM P value
Connectivity Density (mm-3)
0.008
SCD +/216.81 ± 21.9
SCD +/+
117.87 ± 8.21
Trabecular Number (mm-1)
0.02
SCD +/4.950 ± 0.22
SCD +/+
4.018 ± 0.24
Trabecular Separation (um)
0.04
SCD +/197.92 ± 9.58
SCD +/+
244.6 ± 16.35
Apparent BMD (mg/cm3)
0.003
SCD +/198.22 ± 9.3
SCD +/+
98.7 ± 18.1
Bone Volume/Total Volume (%)
0.002
SCD +/17.73 ± 0.85
SCD +/+
9.77 ± 1.38

The numerical data representing the cortical reconstruction in Figure 3C is
presented in Table 4. The cortical bone of the SCD +/+ mice is significantly thinner, has
less BMD and cortical volume, and has a higher marrow volume compared to SCD +/values. The mechanical data represented in Table 4 reveal a significant decrease in the
bone strength of the SCD +/+ femurs compared to the SCD +/- femurs.
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Table 4. High-resolution micro-computed tomography (micro-CT) means ±
standard error of the mean (SEM) data from 9 femurs, 4 SCD+/+, and 5
SCD+/-, and Mechanical Data means include the flexure load in Newtons at
break for 4 SCD+/+, and 5 SCD+/- femurs (3 point bending). Two tailed
independent T-Tests were used to compare the means.
Cortical Bone (Femur)
Mean ± SEM P value
Thickness (µm)
0.001
SCD +/253 ± 6.15
SCD +/+
189 ± 3.78
Bone BMD (mg/cm3)
0.003
SCD +/1284 ± 4.16
SCD +/+
1223 ± 8.92
3
Cortical volume (mm )
0.007
SCD +/0.569 ± 0.02
SCD +/+
0.5 ± 0.01
Marrow volume (mm3)
0.034
SCD +/0.95 ± 0.08
SCD +/+
1.3 ± 0.10
Apparent BMD (mg/cm3)
0.001
SCD +/1219
SCD +/+
1144
Mechanical Data
Flexure load at Break (Newtons)
SCD +/SCD +/+

0.002
29.3 ± 3.3
9.0 ± 1.1

Table 5 shows the trabecular bone difference between the SCD +/+ and SCD +/+
femurs. The homozygous SCD mice have a significantly smaller trabecular number than
the heterozygous mice, as well as a greater trabecular separation between the trabeculae
than the heterozygous mice. Significance tests were performed for each category of data
in the tables, with significance values for each measurement taken.
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Table 5. High-resolution micro-computed tomography (micro-CT) means data
from 9 femurs, 4 SCD+/+, and 5 SCD+/-. Mechanical means data includes
the flexure load in Newtons at break for 4 SCD+/+, and 5 SCD+/- femurs.
Values are expressed as Mean ± standard error mean. Student’s t tests were
performed for each measurement, and p values are all statistically significant
(<0.05).
Trabecular Bone (Femur)
Mean ± SEM
Trabecular number (1/mm)
SCD +/3.55 ± 0.17
SCD +/+
Trabecular separation (mm)
SCD +/SCD +/+
Connectivity density (mm-3)
SCD +/SCD +/+
Apparent BMD (mg/cm3)
SCD+/SCD +/+
Bone Volume/ Total Volume (%)
SCD +/SCD +/+

P value
0.04

3.01 ± 0.13
0.039
.284 ± 0.01
.337 ± 0.02
0.009
95.5 ± 16
26.1 ± 6.9
0.002
130.8 ± 14.8
39.48 ± 17.8
0.01
8.14 ± 0.81
4.71 ± 0.58

DISCUSSION
Micro CT data generate the conclusion that sickle cell disease results in a variety
of bone abnormalities. The data strongly suggests that SCD results in a reduction in BMD
and BMC, and is responsible for the abnormal development of the long bones and
vertebrae.
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CHAPTER 2: NAC TRIAL
Sickle cell disease results in continuous hemolysis of red blood cells, which leads
to the release of free hemoglobin and iron into the bloodstream. These molecules act as
free radicals upon release from red blood cells and can contribute to the damage
associated with the disease. A trial was designed using N-acetyl-L-cysteine (NAC), a
commonly used pharmaceutical drug, to increase glutathione production. NAC is a
commonly used mucolytic agent, as well as a treatment for acetaminophen overdose.
Glutathione is an antioxidant that serves to reduce free radicals, and it could be effective
in reducing the free radicals released into circulation upon red blood cell hemolysis, and
subsequently reduce the bone damage associated with SCD.
In order to address the issue of bone damage associated with an increase in free
radicals, sickle cell mice were produced by bone marrow transplantation and
subsequently treated with NAC. Twenty-three C57Bl/6 female mice received total body
irradiation followed by immediate bone marrow transplant with bone marrow from
homozygous, transgenic BERK sickle cell mice. Homozygous sickle animals were used
to compare the effects of NAC treatment on the progression of the disease. Because it
takes 12 weeks to completely repopulate bone marrow after transplantation, the trial was
initiated 10 weeks after transplantation. The mice were injected subcutaneously 5 times a
week for up to 24 weeks with NAC solubilized in phosphate-buffered saline and adjusted
to physiological pH. Three animals were sacrificed at the time the NAC-injections began
at 10 weeks and were designated as time zero controls. The other 20 mice were separated
into groups of five animals, 2 control groups (uninjected and PBS-injected) and 2
experimental groups (NAC-injected for 12 weeks and NAC-injected at 24 weeks). Upon
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euthanasia, the animals were x-rayed with a DEXA machine that produced BMD and
BMC measurements for the whole body (minus the skull), lumbar vertebrae and femurs.
To determine if the BMT was successful, hemoglobin electrophoresis was
performed at the end of 24 weeks using a blood sample from each animal (results not
shown). The results from the electrophoresis suggest that four of the animals were
partially repopulated with wild type C57Bl/6 bone marrow instead of being almost
completely repopulated with progeny of the homozygous sickle cell bone marrow. One
animal was excluded from the 12-week NAC-injected group, one from the vehicleinjected group and two from the 24-week NAC-injected group. The presence of wild type
bone marrow would increase the number of healthy red blood cells, so that the animals
would have less devastating effects from the SCD. Because this ineffective marrow
repopulation could affect the results thereby obscuring the results of the NAC treatment,
the data collected from those four animals was excluded from the trials before analysis.
Two out of the five total animals were excluded from the 24-week treatment group, so
those results were inconclusive.
RESULTS
DEXA analysis was used to compare the BMD of each animal in the trial and a
separate graph was constructed for each ROI. Figure 4 shows average whole body BMD
(excluding the skull) at the experimental time points. Student’s t tests were performed to
compare average control BMD to average treatment BMD at each time point. There was
no significant difference in the BMD of the control and NAC-treated animals at each time
point, but there is a significant increase in BMD of both control and treatment groups
from 12 compared to both groups at 24 weeks. This suggests that the animals had an
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increase in BMD from 12-24 weeks, but there was no significant change from 0-12
weeks.

NAC Trial Whole Body BMD
*
0.05
0.04
0.03
0.02

Control
TZ n=3
12W n=5
24W n=4
NAC-Treated
12W n=4
24W n=3

0.01
0.00

Time Zero

12 Week

24 Week

Figure 4. Bone Mineral Density (BMD) data for the whole body (excluding the skull). Xray densitometry was performed for control and treated Sickle Cell mice at Time Zero, 12
Weeks and 24 Weeks after administering NAC 5 days/week. Control animals received
either no injection or vehicle injection. Graphs are expressed as means with standard
error. Student t tests were performed for each region of interest (ROI) where all values
were statistically significant, as indicated by * (p < 0.05). The sample number (n) for
each control and NAC-treated group is listed in the figure legend.

Similarly, the BMC measurements were collected for the whole body (excluding
the skull) for each animal; average values were calculated for each group, and those
values are presented in Figure 5. Averages for control and treatment groups were
compared at each time point, as well as one time point to another. Consistent with the
whole body BMD results, there was no significant change between the control and NACtreated animals at each time point. There was a significant increase in BMC from 12-24
weeks, which suggests the control and treatment animals had an increase in BMC for the
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whole body during the trial. The BMC increase was more likely to occur from normal
bone development rather than from NAC-treatment.

NAC Trial Whole Body BMC
**
0.4
0.3
0.2

Control
TZ n=3
12W n=5
24W n=4
Treatment
12W n=4
24W n=3

0.1
0.0

Time Zero

12 Weeks

24 Weeks

Figure 5. Bone Mineral Content (BMC) data for the whole body (excluding the skull). Xray densitometry was performed for control and treated Sickle Cell mice at Time Zero, 12
Weeks and 24 Weeks of administering NAC 5 days/week. The 12-week control animals
received no injection, and the 24-week control animals received injection of the vehicle
PBS. Graphs are expressed as means with standard error. Student t tests were performed
for each region of interest (ROI) where all values were statistically significant, as
indicated by * (p < 0.05) or ** (p < 0.001). The sample size (n) for each control and
NAC-treated group is listed in the figure legend.

After the whole body DEXA scanning was complete, one femur from each animal
was removed and scanned to compare BMD values for each control and treatment group.
Average BMD values were calculated and plotted for each group in Figure 6. Statistical
analysis reveals that there is a significant difference in the BMD of the femurs between
the NAC-treated and control animals at 12 weeks. This difference supports the
conclusion that NAC-injection helped protect the bone from damages associated with
SCD because BMD values were higher than untreated animals. The data demonstrate that
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the NAC-injected animals had significantly higher BMD values than the animals that
received no injections. There was no significant difference between the BMD measured
at time zero compared to 12 weeks, or BMD measured at 12 weeks compared to 24
weeks. The 24-week data is inconclusive because two animals were removed from the
24-week data due to insufficient irradiation of wild type bone marrow. The control group
appears to have higher BMD than the NAC-treated animals at 24 weeks, but this
information is not meaningful due to having BMC averages of only three NAC-injected
animals.

NAC Trial Femur BMD
Control
TZ n=3
12W n=5
24W n=4
NAC-Treated
12W n=4
24W n=3

*

0.05
0.04
0.03
0.02
0.01
0.00

Time Zero

12 Weeks

24 Weeks

Figure 6. DEXA Bone Mineral Density (BMD) data for one excised femurs from each
animal at Time Zero, 12 Weeks and 24 Weeks after administering NAC. The 12-week
control animals received no injection, and the 24-week control animals received injection
of the vehicle PBS. Graphs are expressed as means with standard error. Student t tests
were performed for each region of interest (ROI) where all values were statistically
significant, as indicated by * (p < 0.05). The sample size (n) for each control and NACtreated group is listed in the figure legend.
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In addition to BMD, BMC measurements were collected for excised femurs from
each animal and results are presented in Figure 7. There was a significant increase in
BMC for both control and treatment groups at 12 weeks when compared to time zero.
Although NAC-treated animals had higher BMC than control animals at 12 weeks, the
difference was not statistically significant. There was no significant difference when the
BMC for each 12-week treatment was compared to each 24-week treatment. As
previously stated, the data collected at 24 weeks was inconclusive because the sample
size of the NAC-treated and control groups was too low to determine significance. The
control group appears to have higher mean BMC than the NAC-treated animals at 24
weeks, but this information is suspect due to having BMC averages of only three NACinjected animals. Although there appears to be a large difference between the control and
treatment groups at 24 weeks, it is not statistically significant due to the small sample
size.
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NAC Trial Femur BMC
0.03

Control
TZ n=3
12W n=5
24W n=4
Treatment
12W n=4
24W n=3

*

0.02

0.01

0.00

Time Zero

12 Weeks

24 Weeks

Figure 7. DEXA Bone Mineral Content (BMC) data for a single femur excised from each
animal. X-ray densitometry was performed for control and treatment Sickle Cell mice at
Time Zero, 12 Weeks and 24 Weeks after administering NAC 5 days/week. The 12-week
control animals received no injection, and the 24-week control animals received injection
of the vehicle PBS. Graphs are expressed as means with standard error. Student t tests
were performed for each region of interest (ROI) where all values were statistically
significant, as indicated by * (p < 0.05). The sample size (n) for each control and NACtreated group is listed in the figure legend.

In order to gain more in depth understanding of the effects of NAC on the femur,
micro-CT was performed on one femur from each animal investigated at 12 weeks.
Although some animals were excluded from the DEXA analysis, all 10 animals were
subject to micro-CT and results are presented in Table 6 below. For the cortical bone
region, the NAC-treated animals had significantly higher average cortical thickness and
lower porosity than the untreated animals. Also, the NAC-treated animals had higher
trabecular bone thickness compared to the untreated animals. The mechanical data
reveals that it took significantly more force (almost 2X) to break the femur in the NAC
group compared to the untreated. A Student’s t test was performed for each measurement,
and all differences presented in Table 6 were statistically significant. Figure 8A shows a
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representative reconstructed cross-sectional image from an untreated control animal and a
NAC-treated animal at 12 weeks. The cortical region of the NAC-treated femur was
significantly thicker than the untreated section, and the marrow area of the bone (hollow
area in the center) appears larger for the untreated section. Figure 8B shows a
representative trabecular reconstruction of the distal femur from an untreated control and
a NAC-treated animal. The NAC-treated section has significantly thicker trabeculae than
the untreated section, and the untreated trabeculae have significantly greater separation
than the treated section. The data produced along with the micro-CT images are presented
in Table 6, where cortical and trabecular thickness is greater for the 12-week NACtreated animals when compared to the untreated control animals. Overall, mechanical and
micro-CT data reveal the NAC-treatment was successful at 12 weeks, because there is a
significant increase in bone strength and thickness in animals injected with NAC when
compared to untreated controls. In addition, the untreated control femurs were weaker
and more porous than the femurs from the NAC-treated group.
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Table 6. Micro-CT and Mechanical Data results for untreated control
animals and NAC-treated animals after 12-weeks of administering
subcutaneous NAC. One femur was excised from each animal and
averages were calculated for cortical and trabecular bone regions for
each group ± SEM. The other excised femur was subject to mechanical
testing and the flexure stress required to break the femur is measured in
Newtons. Student t tests were performed for each measurement and all
values of p < 0.05 are statistically significant.
12-Week Femur Micro-CT Results
Cortical Bone
Mean ± SEM
Ct. Thickness (µm)
Untreated
145.90 ± 4.91
NAC
194.63 ± 16.69
Ct. Porosity
Untreated
7.18 ± 0.23
NAC
5.43 ± 0.46
Trabecular Bone
Tb. Thickness (µm)
Untreated
0.036 ± 0.002
NAC
0.050 ± 0.003
Mechanical Data (N)
Untreated
8.36 ± 0.06
NAC
16.19 ± 0.34

A: Cortical Section
Untreated

P value
0.048
0.028

0.028
0.001

B: Trabecular Reconstruction
NAC

Untreated

NAC

Figure 8. Micro-CT analysis. (A) Reconstructed cross-sectional images from the middiaphyseal region of the femurs. (B) Reconstructed trabecular bone from the heads of
femurs. Image Processing Language software from Scanco was used for image
reconstruction.
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After analyses of the femurs, vertebrae were excised from all the animals for
DEXA analysis. Average BMD values were calculated for the lumbar vertebrae for the
control and treatment groups in Figure 9. There was a significant difference between
control and NAC-treated groups at 12 weeks. There was a decrease in BMD measured at
time zero compared to BMD at 12 and 24 weeks. Therefore, the NAC conferred some
advantage at 12-weeks, but the small sample size compared at 24-weeks did not provide
meaningful results. Repetition using a higher concentration of NAC is required to
resolve this issue. The significant decrease in BMD from time zero to 12 weeks was
interesting because it did not occur in any other ROI. At 12 weeks the NAC-treated
animals had a higher average BMD than the untreated animals, but the difference was not
significant.

NAC Trial Lumbar Vertebrae BMD
Control
TZ n=3
12W n=5
24W n=4
NAC-Treated
12W n=4
24W n=3

*

0.03

0.02

0.01

0.00

Time Zero

12 Weeks

24 Weeks

Figure 9. DEXA Bone Mineral Density (BMD) data for excised lumbar vertebrae from
control, and treated Sickle Cell mice at 12 weeks and 24 weeks of administering NAC, as
well as for the Time Zero controls. The 12-week control animals received no injection,
and the 24-week control animals received injection of the vehicle PBS. Graphs are
expressed as means with standard error. Student t tests were performed for each region of
interest (ROI) where all values were statistically significant, as indicated by * (p < 0.05).
The sample size (n) for each control and NAC-treated group is listed in the figure legend.

32	
  

BMC measurements were also obtained for the lumbar vertebrae and average
values are depicted graphically in Figure 10. Consistent with BMD averages for lumbar
vertebrae, the average BMC content decreased from time zero to 12 and 24 weeks, but
the decrease did not prove to be significant. There was a significant decrease in BMD
measured at time zero when compared to both 12-week groups. The average BMC for
NAC-treated animals was higher than the untreated control animals at 12 weeks, but also
was not statistically significant. These findings are consistent with the data in Chapter 1
that suggests SCD has detrimental effects on the lumbar vertebrae.

NAC Trial Lumbar Vertebrae BMC
0.02

Control
TZ n=3
12W n=5
24W n=4
NAC-Treated
12W n=4
24W n=3

0.01

0.00

Time Zero

12 Weeks

24 Weeks

Figure 10. DEXA Bone Mineral Content (BMC) data for excised lumbar vertebrae for
control, and treated Sickle Cell mice at 12 weeks and 24 weeks of administering NAC, as
well as for the Time Zero controls. The 12-week control animals received no injection,
and the 24-week control animals received injection of the vehicle PBS. Graphs are
expressed as means with standard error. Student t tests were performed for each region of
interest (ROI) and there were no significant values. The sample size (n) for each control
and NAC-treated group is listed in the figure legend.
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The spleens of the BERK mice become unnaturally large (splenomegaly), and it
could be a consequence of SCD-induced hemolysis. In addition to the red bone marrow,
red blood cells are produced in the spleen. Hemolysis occurs as a consequence of red
blood cell sickling, and therefore leads to an increase in the production of white blood
cells (WBC) and RBCs in the spleen because production of RBCs in the bone marrow
cannot compensate for the loss due to hemolysis. This results in an enlargement of the
spleen. After bone differences were evaluated, the spleens were weighed to see whether
or not the NAC-treatment had an effect on the size of the spleen. The data in Figure 11
demonstrate a significant increase in size from time zero to 12 weeks, which is consistent
with the progression of the disease. Interestingly, there is an inhibition of enlargement of
the spleens in the NAC-treated animals compared to the untreated control animals at 12
weeks. NAC-treatment had a positive effect on rate at which the spleen enlarges, but
whether this was a direct or indirect effect of the treatment is unknown. Because some
animals were excluded at 24 weeks due to problems with the BMT, the spleen weight
data is inconclusive at that time point.

34	
  

Figure 11. Spleen weights. The spleens from all of the animals were excised and weighed
after euthanasia. Student t tests were performed for each control and treatment group at
each time point. Statistically significant differences are indicated by ** (p < 0.001).

DISCUSSION
Overall, there were some interesting results from the NAC trial. First, there was a
significant increase in both BMD and BMC for the whole body animal scans from the
control and treatment groups from 12 to 24 weeks. This increase is not a consequence of
the NAC treatment, but may reflect bone growth. For the excised femurs, there was a
significant increase in the BMD of NAC-treated animals at 12 weeks relative to the
untreated controls. Femur BMC was significantly higher in both control and treated
animals at 12 weeks when compared to time zero. This suggests the animals were
increasing in bone mass during this time, but this conclusion is speculation. Injection
with NAC was successful for the BMD of the femur at 12 weeks because the NACtreated group had significantly higher BMD than controls at that time point. The lumbar
vertebrae appear to be affected more extensively than the long bones by SCD, because
there was a significant decrease in BMD at 12 weeks for both control and treatment
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lumbar vertebrae groups relative to time zero. This is consistent with the effects of SCD
in patients; the lumbar vertebrae have a propensity for developing a BMD loss relative to
other bones (Miller et al., 2006; Sarrai, Duroseau, D'Augustine, Moktan, & Bellevue,
2007). The NAC-treatment seemed to confer some protection up to 12 weeks, because
NAC-treated animals had a significantly higher BMD than untreated animals. There was
also a decrease in average BMC of the lumbar vertebrae from time zero to 12 weeks, but
it was not significant. The NAC trial seemed to have a beneficial effect on the spleen at
the 12-week time point of the trial, as there was a significant decrease in the spleen
weight of the NAC-treated animals compared to the untreated control animals. For all
ROI’s and spleen measurements taken, the animals at 24 weeks did not produce
conclusive results due to the several animals that were eliminated from the trial after it
was discovered that some animals had repopulation of wild type C57Bl/6 bone marrow
which could produce some level of healthy hemoglobin. Therefore, the sample size (N)
was too small to provide meaningful data.
In retrospect, it would have been more beneficial to run the hemoglobin
electrophoresis at time zero and eliminate the animals from the trial in the beginning that
were able to repopulate with wild type bone marrow. The animals with wild type bone
marrow could have higher DEXA values, which would confuse the results and could
wrongfully suggest that NAC was responsible for the stronger bones. A larger sample
size of 10 animals would provide more conclusive results than 5, and would allow for
more conclusive statistical analyses in case some animals were lost or excluded from the
trial. Also, being able to perform the DEXA scans on the animals every other week could
have provided more insightful information, so it would be more beneficial to house the
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animals at an institution with a DEXA available and inject them daily at that facility.
Therefore, the NAC trial demonstrates that NAC appeared to be able to counteract some
deleterious effects of SCD, and provides some insights for an improved NAC trial
protocol that could be performed in the future.
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Chapter 3: Brain Characterization
The blood brain barrier in Berkeley SCD mice is more permeable than wild type
mice (Manci et al., 2006). The increased permeability of the blood barrier may be due to
the inflammation associated with SCD leading to monocyte penetration into brain tissue
of SCD mice. In order to address this hypothesis, brains from all 23 SCD mice used for
the NAC trial were removed, sectioned, stained for monocyte infiltration, and serially
mounted for microscopic observation. Staining was scored using Image J software to
quantify the number of immunoreactive monocytes in each brain; differences between
treatment groups were analyzed using ANOVA.
In order to assess monocyte infiltration of the brain, sections were incubated with
a monocyte-specific antibody (Moma-2, monoclonal Rat anti-mouse), stained and
prepared for observation. The brains were serially sectioned and mounted on microscope
slides and viewed for monocyte staining. Figure 12 illustrates representative sections
from each group. Staining occurred in each brain in the hippocampus and caudate
putamen (striatum), which is consistent with literature addressing the effects of increased
peripheral inflammation on monocyte infiltration of the brain (D'Mello et al., 2009). The
staining in each sectioned brain supported the hypothesis that the constant inflammatory
state associated with SCD results in enhanced monocyte penetration of the blood brain
barrier, presumably because of the increased permeability of the blood brain barrier
resulting from SCD.
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RESULTS

Figure 12. SCD Brain Sections. Images taken from SCD animals used for the NAC trial
at Time Zero, Untreated animals at 12 weeks and PBS-injected control and NAC-injected
animals at 24 weeks. Images were taken at a 10X magnification of 30µm sections brain
sections after incubation with a primary MOMA-2 antibody and secondary anti-rat IgG
antibody that recognizes and binds to an intracellular antigen of monocytes. NickelDab
stain was used for the identification of monocytes.

Due to the background staining in some sections such as the time zero sections in
Figure 12, Image J analysis software was used to set a specific threshold and intensity of
staining to isolate the stained monocytes from non-specific background staining. This
was accomplished by taking a picture of each brain region at 10X and using the same
parameters for consistent analysis. After quantification of monocyte staining, an ANOVA
was used to compare the number of immunoreactive monocytes among groups, where

39	
  

variances did not differ significantly among groups at three time points F (4,18)= 1.547
(F-value), p = 0.230.
The number of monocytes present in the striatum of each group is expressed
graphically in Figure 13. The highest average number of monocytes was observed in the
time zero group, with an average of 10 cells per section. Next there were 8.4 cells stained
in the 24 week NAC group, followed by 7.8 in the PBS-injected controls, 7.4 in the 12
week NAC treatment group and the lowest average cell count occurred in the uninjected
control group with 6.6 cells. Interestingly, the highest average counts occurred in the time
zero controls compared to all other groups.

12

Interaction Bar Plot for Striatum
Effect: Treatm ent

Cell Mean

10
8
6
4
2
0

TZ

U

PBS
Cell

NAC12

NAC24

Figure 13. ANOVA results for the striatum brain region at time points of Time zero,
uninjected control (U), vehicle-treated control (PBS), NAC-treated at 12 weeks (NAC12)
and NAC-treated at 24 weeks (NAC24). Means were taken from Image J analysis of one
section from each animal and cell means were graphed ± standard error.
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Although the ANOVA produced an insignificant F value, post hoc analysis was
performed to investigate a planned comparison. A planned comparison was used to
determine if NAC-treatment had an effect on monocyte migration, which was part of the
initial experimental design. The results from the Fisher’s PLSD for the striatum are
depicted in Table 7, and the only comparison that produced a significant p-value was
time zero compared to uninjected control. Although the means for each group were
different and appeared to be slightly higher in the control and treatment groups at 24
weeks when compared to 12 weeks, there was no statistically significant difference
between any two groups except the time zero and 12 week uninjected controls.

Table 7. ANOVA post hoc results. The Fisher’s protected least significant difference
(Fisher’s PLSD) results comparing monocyte staining in the striatum for each control and
experimental group against all other groups. The table shows the Mean difference and
Critical Difference between the compared groups and a student’s t test produces a p-value
where p< 0.05 is statistically significant (indicated by an S next to the significant pvalue).
Fisher's PLSD for Striatum
Effect: Treatm ent
Significance Level: 5 %
Mean Diff.

Crit. Diff.

P-Value

TZ, U

3.400

3.034

.0301 S

TZ, PBS

2.200

3.034

.1451

TZ, NAC12

2.600

3.034

.0886

TZ, NAC24

1.600

3.034

.2825

U, PBS

-1.200

2.628

.3501

U, NAC12

-.800

2.628

.5305

U, NAC24

-1.800

2.628

.1673

.400

2.628

.7528

-.600

2.628

.6372

-1.000

2.628

.4344

PBS, NAC12
PBS, NAC24
NAC12, NAC24
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In addition to the striatum, the hippocampal region of the brain stained positive
for monocytes. The hippocampus is important for consolidating short-term memory with
long-term memory and also plays a role in orientation. Damaging the hippocampus can
result in complications related to learning and memory, such as Alzheimer’s disease, but
has not been described for sickle cell patients. Hypoxia can result in short-term amnesia
and disorientation. The results from the ANOVA reveal that the variances did not differ
significantly across the groups at three time points F (4,18)= 1.841 (F-value), p = 0.1650.
The mean calculated for stained monocytes present in the hippocampus for each
control and experimental group is expressed in Figure 14. The group with the highest
number of stained monocytes per section was the 24-week NAC group with 8.8 cells,
followed by time zero with 7.7 cells, 24-week control PBS group with 7.0, 12-week
Uninjected control group with 6.6 and the lowest number of stained monocytes occurred
in the 12-week NAC group with 5.8 cells. When the averages graphed for each group are
compared (Figure 14), it appears there was less staining in both control and treatment
groups at 12 weeks when compared to time zero. This is consistent with staining from the
striatum. There was an increase in staining in the control and treatment groups at 24
weeks when compared to 12 weeks, although differences are not significant. This
suggests the progression of the disease results in increased establishment of monocytes in
the brain, which could increase the risk of short-term memory loss, disorientation or other
problems associated with damaged hippocampus, which would add to the pleiotropic
effects of SCD.
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Figure 14. ANOVA results for the striatum brain region at time points of Time zero,
uninjected control (U), vehicle-treated control (PBS), NAC-treated at 12 weeks (NAC12)
and NAC-treated at 24 weeks (NAC24). Means were taken from Image J analysis of one
section from each animal and cell means were graphed ± standard error.

Although the ANOVA produced an insignificant F value, post hoc analysis was
performed to investigate a planned comparison. A planned comparison was used to
determine if NAC-treatment had an effect on monocyte migration, which was part of the
initial experimental design. The results from the Fisher’s PLSD for the striatum are
illustrated in Table 10, and the only comparison that produced a significant p-value was
the NAC-treated group at 12 weeks compared to the NAC-treated at 24 weeks. Although
the treatment was higher at 24 weeks, the fact that the NAC treated at 12 weeks was
significantly lower suggests that the NAC could be having a positive effect on monocyte
recruitment into the brain since the average was significantly lower for that group than
the 24-week group. This very tentative concept is further supported by the fact that the
control animals at 12 weeks (U) had higher number of stained monocytes than the 12week NAC treated animals.
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Table 8. ANOVA post hoc results. The Fisher’s protected least significant difference
(Fisher’s PLSD) results comparing monocyte staining in the hippocampus for each
control and experimental group against all other groups. The table shows the Mean
difference and Critical Difference between the compared groups and a student’s t test
produces a p-value where p< 0.05 is statistically significant (indicated by an S next to the
significant p-value).
Fisher's PLSD for Hippocam pus
Effect: Treatm ent
Significance Level: 5 %
Mean Diff. Crit. Diff.
TZ, U

P-Value

1.067

2.835

.4396

.667

2.835

.6273

TZ, NAC12

1.867

2.835

.1835

TZ, NAC24

-1.133

2.835

.4120

-.400

2.455

.7361

U, NAC12

.800

2.455

.5024

U, NAC24

-2.200

2.455

.0761

PBS, NAC12

1.200

2.455

.3181

PBS, NAC24

-1.800

2.455

.1409

NAC12, NAC24

-3.000

2.455

.0194 S

TZ, PBS

U, PBS

DISCUSSION
Overall, the brain sectioning provided insight into the ability of monocytes to pass
through the blood brain barrier and establish in the striatum and hippocampal regions of
the brain. The mechanism by which the blood brain barrier becomes more permeable is
not currently known, and it would be beneficial to determine that mechanism to prevent
immune cells from invading the brain in instances of increased peripheral inflammation
such as sickle cell disease. In addition to the interference in normal brain function in
response to monocyte infiltration the brain, hypoxia can result in stroke and other
potentially harmful conditions. The hypoxia that occurs from sickled cells blocking blood
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flow to the brain commonly results in stroke in SCD patients. Ischemia, in combination
with immune cell damage to the brain, could result in a serious brain damage and
memory loss and requires further investigation.
OVERALL CONCLUSION
The data presented in Chapter 1 strongly suggest that the Berkeley mouse model
appears to be appropriate for studying bone abnormalities associated with SCD. Before
this study, there were insufficient data in the literature addressing the effects of SCD on
the development of bone abnormalities in humans or mice. This chapter characterizes the
effects of SCD on BMD and BMC in the BERK mouse model, and also provides an in
depth investigation of bone morphology as a consequence of the disease. In addition, the
BERK mouse model provides a potentially very useful vehicle for testing the effects of
potential SCD therapeutic agents on the development of SCD related bone abnormalities.
Chapter 2 addressed the ability of the therapeutic agent, NAC, to rescue the
BERK skeleton from the progression of bone abnormalities associated with SCD by
enhancing antioxidant production. The treatment was successful in preventing bone
deficiencies from occurring for a time period of 12 weeks, and also reduced
splenomegaly that is a known consequence of SCD for mice. This is critically important
information because bone abnormalities are a very serious and universal aspect of SCD
and few, if any, therapeutic agents have been tested for their effect on the development or
treatment of SCD elicited bone abnormalities.
Finally, Chapter 3 investigated the ability of immune cells to migrate across the
blood brain barrier as a consequence of increased permeability, as well as the effects of
NAC on migration. Monocytes were present in the brain tissue of all animals, which has
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not been previously described. Statistical analysis proved that NAC had no beneficial
effect on migration compared to untreated animals. Overall, this study gives a detailed
assessment of the bone and brain abnormalities that occur as a consequence of SCD, and
support the use of the BERK mouse model to further investigate the pleiotropic effects of
SCD in an attempt to develop therapeutic treatments for patients.
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